Investor Relations Home

Profile
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.

The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts.  We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues.  It is possible that the information we post on social media channels could be deemed to be material information.  We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
Stock Quote
IRIX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$15.00
Change (%) Stock is Down 0.42 (2.72%)
Volume33,306
Data as of 12/06/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
11/07/16IRIDEX to Present at Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Nov. 7, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that management is scheduled to present at the following investor conferences in New York City: The Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016, at 8:00 am ET. The Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016, at 11:50 a.m. ET. Live audio webcasts of the presentations may be accessed on the Event Calendar of the I... 
Printer Friendly Version
11/03/16IRIDEX Reports 2016 Third Quarter, Nine-Month Results
Cyclo G6™ Glaucoma Laser Platform Third Quarter Revenues Up 442 Percent Year-over-Year MOUNTAIN VIEW, Calif., Nov. 3, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended October 1, 2016.  Revenues were $9.8 million for the third quarter of 2016, flat from $9.8 million for the 2015 third quarter.  Growth in revenues from the Company's Cyclo G6™ glaucoma laser platform, which increased 442 percent compared to ... 
Printer Friendly Version
10/27/16IRIDEX Announces Third Quarter 2016 Conference Call and Release Date
MOUNTAIN VIEW, Calif., Oct. 27, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2016 financial results after the market closes on Thursday, November 3, 2016.  In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, November 3, 2016 to discuss the results of the quarter and other business developments. Interested parties may access the live confe... 
Printer Friendly Version
10/11/16IRIDEX Announces Preliminary Revenues for 2016 Third Quarter
MOUNTAIN VIEW, Calif., Oct. 11, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported preliminary revenues of approximately $9.6 to $9.7 million for the third quarter ended October 1, 2016 compared to prior revenue guidance of $11.0 to $11.3 million.  While demand for the Company's new flagship Cyclo G6™ laser platform for glaucoma remained strong, revenues of certain retina products were below expectations although the Company ended the third quarter with a record high in back o... 
Printer Friendly Version
Primary IR Contact
Atabak Mokari
CFO and VP, Corporate Development
Phone: 650-605-8716
E-mail: amokari@iridex.com

Matt Clawson
Pure Communications
Phone: 949-370-8500
E-mail: matt@purecommunicationsinc.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


logo aa0logo agslogo ascrslogo asrslogo esrs0logo euretina